Can a vaccine protect the vulnerable? new study targets HPV in ICL patients
NCT ID NCT03519464
First seen Dec 12, 2025 · Last updated May 06, 2026 · Updated 29 times
Summary
This study tests whether the HPV vaccine (Gardasil 9) can help people with a rare immune condition called ICL, who are more prone to severe HPV-related diseases. About 54 adults with ICL and some healthy volunteers will receive three vaccine doses over six months. Researchers will measure immune responses and safety to see if the vaccine offers protection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC CD4 T CELL LYMPHOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.